Antiretroviral Therapy
Active Resources: 51
-
Training slides review potential ARV drug-drug interactions and identify resources for the evaluation of drug-drug interactions.
Type: Training MaterialsPublish Date: 9/22/2021 -
Dr. Adrienne E Shapiro discusses highlights from the 2021 IAS Conference.
Type: Training MaterialsPublish Date: 8/13/2021 -
This session covers how different HIV medication classes function to suppress viral replication, and reviews current HIV treatment medications and newer HIV treatment regimens.
Type: Webinar RecordingsPublish Date: 7/29/2021 -
Learning Objectives:
- Recall processes and data from long-acting antiretroviral clinical trials
- Discuss why patients may desire long-acting antiretroviral therapy
Type: Training MaterialsPublish Date: 7/15/2021 -
This quick guide for clinicians discusses the drug interactions between Sofosbuvir/Velpatasvir/Voxilaprevir(Vosevi®)
Type: Articles, Reports, and ManualsPublish Date: 7/14/2021 -
This quick guide for clinicians discusses the drug interactions between Sofosbuvir/Velpatasvir (Epclusa®)
Type: Articles, Reports, and ManualsPublish Date: 7/14/2021 -
This quick guide for clinicians discusses the drug interactions between Ledipasvir/Sofosbuvir(Harvoni®)
Type: Articles, Reports, and ManualsPublish Date: 7/14/2021 -
This quick guide for clinicians discusses the drug interactions between Glecaprevir/Pibrentasvir (Mavyret™)
Type: Articles, Reports, and ManualsPublish Date: 7/14/2021 -
This quick guide for clinicians discusses the drug interactions between Elbasvir/Grazoprevir (Zepatier™)
Type: Articles, Reports, and ManualsPublish Date: 7/14/2021 -
Training slides provide a review of the following updated sections to the US Dept. of Health & Human Services (HHS) Adult and Adolescent HIV Treatment Guidelines:
Type: Webinar RecordingsPublish Date: 7/2/2021 -
Below is a list of the newest (2021) pocket guides created by the MidAtlantic AETC. Descriptions for each resource can be found here:
Type: Clinical Reference ToolsPublish Date: 7/2/2021 -
Training slides provide a summary of data from the ATLAS and FLAIR studies and outlines a case for patient eligibility for long-acting injectable ART.
Type: Training MaterialsPublish Date: 7/1/2021 -
To help HIV care providers engage patients in care and transmission prevention, the Centers for Disease Control and Prevention (CDC) developed a new and comprehensive Prevention IS Care re
Type: Clinical Reference ToolsPublish Date: 6/30/2021 -
Training slides covering U.S. HHS treatment recommendations related to starting antiretroviral therapy (ART) in people with HIV infection.
Type: Training MaterialsPublish Date: 6/10/2021 -
Immediate antiretroviral therapy (ART) means starting HIV treatment as soon as possible after the diagnosis of HIV infection, preferably on the first clinic visit (and even on the same day as the H
Type: GuidelinesPublish Date: 6/10/2021 -
Recommended management strategies for HIV patients experiencing virologic failure (VF) while taking antiretroviral therapy (ART).
Type: Training MaterialsPublish Date: 6/10/2021 -
Excerpt from the Guidelines Introduction: "The Department of Health and Human Services (HHS) Panel on Antiretroviral Guidelines for Adults and Adolescents (the Panel) is a working group of
Type: GuidelinesPublish Date: 6/3/2021Review Date: 7/5/2021 -
New England AETC's HIV Resource Library is a compilation of curated resources and education packets on HIV, viral hepatitis, and related public health topics.
Type: Training MaterialsPublish Date: 5/27/2021 -
Training slides provide updates on tuberculosis in people with HIV including prevalence, prevention, and treatment.
Type: Training MaterialsPublish Date: 5/24/2021 -
Training slides cover initial antiretroviral therapy (ART) options based on the most recent HHS Adult/Adolescent Guidelines.
Type: Training MaterialsPublish Date: 4/29/2021 -
(Recorded on April 12, 2021)
Speaker:
Paul Edward Sax, MD
Type: Webinar RecordingsPublish Date: 4/21/2021 -
Presentation slides include information and updates from CROI 2021 regarding:
- IMPACT 2010
- ATLAS-2M
- Lenacapavir: Capella Study
Type: Training MaterialsPublish Date: 4/19/2021 -
The HIV epidemic is an important public health priority. Transmissions continue to occur despite effective therapies that make HIV preventable and treatable.
Type: Articles, Reports, and ManualsPublish Date: 4/15/2021 -
Training slides review the latest information on HIV injectable therapies in clinical trials, the patients who might be good candidates for this treatment, and potential challenges for provide
Type: Training MaterialsPublish Date: 2/22/2021 -
Training slides provide an overview of Cabenuva including the latest study findings, adverse effects, resistance, and special dosing considerations.
Type: Training MaterialsPublish Date: 2/22/2021 -
Session 4 of the AETC Program HIV and SARS-CoV-2 Winter Webinar Series (recorded 1/27/21). Presenters discussed the clinical impact of HIV infection and COVID-19, analyzed
Type: Webinar RecordingsPublish Date: 2/9/2021 -
This provider resource offers practical guidance on what to consider when prescribing pre-exposure prevention (PrEP) for patients at risk of HIV infection.
Type: Clinical Reference ToolsPublish Date: 1/11/2021 -
The Pacific AETC’s HIV Learning Network (HIVLN) is a free, longitudinal tele-health HIV training and consultation program for HIV clinical care teams and individual clinicians in the Pacific Region
Type: Online and Self-Paced LearningPublish Date: 12/31/2020Review Date: 10/4/2021 -
Excerpt from Introduction: The Department of Health and Human Services Panel on Treatment of HIV-Infected Pregnant Women and Prevention of Perinatal Transmission, a working group of t
Type: GuidelinesPublish Date: 12/30/2020Review Date: 7/5/2021 -
Guidelines for treating HIV-infected infants, children, and adolescents, including clinical monitoring, initiation of treatment, pediatric-specific drug information, and managing complications.
Type: GuidelinesPublish Date: 12/20/2020Review Date: 7/5/2021 -
A basic overview of resistance testing and key aspects of medications used in treatment-experienced patients, review newer medications and their role in HIV treatment.
Type: Training MaterialsPublish Date: 10/30/2020 -
About the Program:
Type: Online and Self-Paced LearningPublish Date: 9/19/2020 -
The National HIV Curriculum (NHC) provides free, up-to-date content for clinicians to learn about HIV diagnosis, treatment, and prevention.
Type: Online and Self-Paced LearningPublish Date: 9/14/2020Review Date: 9/8/2021 -
Slides from a 2-day training program for primary health and social service providers, which combines recent research with practical guidelines for a comprehensive approach to the care of persons wi
Type: Online and Self-Paced LearningPublish Date: 7/31/2020 -
Slides from a 1-day course for primary care physicians and mid-level clinicians, which combines the latest research with current treatment guidelines for managing patients with HIV.
Type: Online and Self-Paced LearningPublish Date: 7/31/2020 -
This slide set includes an overview of cabotegravir, and provides updates from the phase III PrEP trial and next steps for long-acting PrEP.
Type: Training MaterialsPublish Date: 6/2/2020 -
Three sets of training slides covering what providers treating people with HIV should know about COVID-19.
Type: Training MaterialsPublish Date: 4/9/2020 -
Training slides cover HHS recommendations for treatment of transgender people with HIV.
Type: Training MaterialsPublish Date: 1/31/2020 -
This training slide set covers aging-related concerns for people with HIV, including management of ART.
Type: Training MaterialsPublish Date: 1/31/2020 -
Each year HRSA's HIV/AIDS Bureau sponsors a conference for Ryan White Program clinicians to learn about advances in care and treatment.
Type: Online and Self-Paced LearningPublish Date: 12/4/2019 -
In response to newly identified, community-based HIV epidemics, the AETC NCRC has pulled together the following AETC Program and U.S.
Type: Clinical Reference ToolsPublish Date: 6/10/2019 -
Type: Clinical Reference ToolsPublish Date: 6/1/2019Review Date: 10/22/2019 -
This glossary of HIV/AIDS-related terms includes brief lay-oriented descriptions and illustrations. Materials are in the public domain and may be used freely.
Type: Clinical Reference ToolsPublish Date: 2/20/2019Review Date: 2/20/2019 -
Northeast/Caribbean (NECA) AETC offers online continuing education accredited videos and monographs.
Type: Online and Self-Paced LearningPublish Date: 2/5/2019Review Date: 6/11/2021 -
A collection of updated clinical guides regarding drug interactions of HCV direct-acting antivirals (DAAs) with other common primary care medications and HIV antiretrovirals.
Type: Clinical Reference ToolsPublish Date: 2/1/2019 -
Type: Clinical Reference ToolsPublish Date: 1/15/2019 -
Type: GuidelinesPublish Date: 7/20/2018
-
This chart was developed to facilitate continuity of care for people living with HIV who may receive care in both the United States and Mexico.
Type: Clinical Reference ToolsPublish Date: 6/20/2018 -
Comprehensive guidelines, including:
Type: GuidelinesPublish Date: 5/24/2018Review Date: 9/2/2020 -
This guide is designed to assist health professionals in evaluating medical and dental considerations for treating people with HIV in the era of ART.
Type: Clinical Reference ToolsPublish Date: 3/12/2018 -
This multi-module curriculum is designed for specifically for Medical Case Managers.
Type: Online and Self-Paced LearningPublish Date: 9/15/2017
Archive Resources: 20
-
Quick guide to oral contraceptives and HIV medications drug interactions.
Type: Clinical Reference ToolsPublish Date: 5/3/2017Review Date: 5/3/2017 -
Objectives
- Identify issues associated with treating older individuals with HIV infection
Type: Online and Self-Paced LearningPublish Date: 12/7/2016 -
Objectives
- Understand how HIV coinfection impacts the natural history of hepatitis C virus (HCV)
Type: Online and Self-Paced LearningPublish Date: 10/26/2016 -
Objectives
- List available HCV direct acting antivirals (DAAs) available for HCV therapy in 2016
Type: Online and Self-Paced LearningPublish Date: 10/12/2016 -
36 evidence-based recommendations are provided for interventions to optimize the HIV care environment; increase HIV testing and linkage to care, treatment coverage, retention in care, and vira
Type: GuidelinesPublish Date: 11/9/2015 -
Infographic provides recommendations to address gaps in the HIV care continuum related to HIV treatment and prevention for women and their partners.
Type: Clinical Reference ToolsPublish Date: 9/4/2015 -
Illustrates how improving patient self-management can help to reduce gaps along the HIV care continuum.
Type: Clinical Reference ToolsPublish Date: 7/1/2015Review Date: 5/18/2021 -
Trainer slide set on HIV among people aged 50 and older.
Type: Training MaterialsPublish Date: 5/19/2015 -
AETC HIV and Aging Workgroup
HIV and Aging ToolkitType: Clinical Reference ToolsPublish Date: 4/1/2015 -
This report, done by The Black AIDS Institute in collaboration with the CDC, the Latino Commission on AIDS, NASTAD, Johns Hopkins Bloomberg School of PublicType: Articles, Reports, and ManualsPublish Date: 2/6/2015
-
Approximately 7/10 people with HIV in the U.S. are not virally suppressed.
Type: Clinical Reference ToolsPublish Date: 1/28/2015 -
Infographic identifies some of the social determinants that correlate to new HIV infections in Black men who have sex with men (MSM).
Type: Clinical Reference ToolsPublish Date: 12/22/2014Review Date: 5/8/2019 -
This guideline is a comprehensive compilation of federal recommendations about biomedical, behavioral, and structural interventions that can help reduce the risk of HIV transmission from persons wi
Type: GuidelinesPublish Date: 12/11/2014 -
The HIV/AIDS Bureau (HAB) of HRSA has developed a series of clinical performance indicators for Ryan White HIV/AIDS
Type: Clinical Reference ToolsPublish Date: 7/31/2014Review Date: 2/12/2018 -
This video describes HIV viral replication and where antiretroviral drugs work in the replication process.
Type: Online and Self-Paced LearningPublish Date: 7/17/2014 -
Patient education video discusses basic information about HIV infection, lab values, and the importance of adherence to ART regimen.
Type: Clinical Reference ToolsPublish Date: 7/7/2014Review Date: 5/8/2019 -
Pocket reference with interaction information and patient education recommendations. Order printed copies online from the NY/NJ AETC.
Type: Clinical Reference ToolsPublish Date: 2/1/2014 -
The 69 slides on Occupational Exposure to HIV, HCV, and HBV provide an overview of basic HIV information as well as fulfill the following objectives:
Type: Training MaterialsPublish Date: 1/15/2014 -
The AETC Program national, regional, and local partners are a part of the HRSA-funded Ryan White HIV/AIDS Program.
Type: Clinical Reference ToolsPublish Date: 6/1/2013Review Date: 1/11/2017 -
After HIV diagnosis, timely entry into HIV medical care and retention in that care are essential to the provision of effective antiretroviral therapy (ART).
Type: GuidelinesPublish Date: 3/5/2012Review Date: 5/17/2019
Articles: 27
-
HIV Meds Updates - Long-acting Injectable Therapy: Cabotegravir + Rilpivirine
The FLAIR study evaluated the efficacy and safety of the long-acting injectable regimen of cabotegravir (CAB) + rilpivirine (RPV) in previously ART-naïve individuals who switched to CAB+RPV after viral suppression on a standard 3-drug oral regimen (dolutegravir [DTG]/ABC/3TC). At both 48 weeks (...
-
HIV Meds Updates - TANGO and SALSA Studies: Switch to DTG/3TC from 3-Drug ART
TANGO is a randomized open-label study in which subjects with virologic suppression on standard 3-drug TAF-based ART either switched to the 2-drug regimen of dolutegravir (DTG)/lamivudine (3TC) (Dovato) n = 369) or continued their baseline ART (n = 372). Previously published...
-
HIV Meds Updates: Long-acting Injectable Therapy: Lenacapavir
Lenacapavir (LEN) is a novel investigational long-acting injectable ARV that is administered every 6 months by subcutaneous (SC) injection. It is an HIV-1 capsid inhibitor that acts at several points in the HIV life cycle. As a novel class, has full activity against viruses with resistance to...
-
Long-acting Injectable PrEP: Cabotegravir
A long-acting formulation of the investigational integrase inhibitor cabotegravir (CAB) is being studied as a single agent for HIV prevention. (CAB also has been studied, in combination with long-acting rilpivirine, as treatment for people with HIV, see Long-Acting Injectable ART: Cabotegravir...
-
New ARV Approval - Fostemsavir
In July 2020, the U.S. Food and Drug Administration approved fostemsavir (FTR) for treatment of people with multi-drug resistant HIV-1 whose current ARV regimen is failing because of resistance, intolerance, or safety issues. FTR is a novel attachment inhibitor that binds the HIV envelope...
-
Safety of Dolutegravir at Conception: Updated Data
In 2018, initial results from the Tsepamo study of birth outcomes in Botswanan women treated with ART during pregnancy raised questions about the safety of dolutegravir (DTG) when given at the time of conception or very early in pregnancy. Specifically, an early interim analysis found a higher...
-
FDA Approves 2-Drug Combination of Dolutegravir + Lamivudine
In April 2019, the U.S. Food and Drug Administration approved a combination pill comprising the integrase inhibitor dolutegravir (DTG), 50 mg, and the NRTI lamivudine (3TC), 300 mg, for use as a complete ARV regimen for initial HIV treatment of patients. The approval specifies that DTG/3TC is...
-
Tenofovir Alafenamide (TAF) and Darunavir/Cobicistat in Pregnant Women
Two pharmacokinetic studies from AIDS 2018 help elucidate the disposition of tenofovir alafenamide (TAF) and cobicistat-boosted darunavir during pregnancy.
The IMPAACT P1026s study examined plasma concentrations of TAF with and without cobicistat in 43 pregnant women. For women taking...
-
U=U in PARTNER2 Study of MSM
PARTNER1, whose results were reported last year,(1) was one of the studies that supported current efforts to promote the growing scientific consensus supporting "Treatment as Prevention" (TasP) or Undetectable = Untransmittable (U=U).
PARTNER1 evaluated HIV transmission risk in a...
-
Darunavir/Cobicistat/FTC/TAF Coformulation Approved; More Data from EMERALD Switch Study
The U.S. Food and Drug Administration has given approval to a coformulation of darunavir 800 mg/cobicistat 150 mg/emtricitabine 200 mg/tenofovir alafenamide (TAF) 10 mg, to be marketed under the brand name Symtuza. DRV/COBI/FTC/TAF constitutes a complete regimen for patients with susceptible HIV...
-
Bictegravir/TAF/FTC in Women
The single-pill combination of bictegravir (BIC) with tenofovir alafenamide (TAF) and emtricitabine (FTC) has been shown in four Phase III trials to be effective as initial therapy.Also as a switch regimen in patients with stably suppressed HIV RNA and no resistance to BIC, TAF,...
-
Darunavir/Cobicistat/FTC/TAF Single-Pill Combination in Treatment-Experienced Patients: EMERALD Study
The EMERALD Study is a Phase III, open-label, noninferiority study in which 1,141 patients with stable HIV suppression on a regimen comprising a boosted protease inhibitor plus TDF/FTC were randomized (2:1) to either switch to an investigational single-tablet regimen containing...
-
Rifampin Drug-Drug Interactions with Newer Antiretrovirals (TAF, Bictegravir, Dolutegravir)
Treatment of tuberculosis (TB) in HIV-infected persons remains challenging, in part because of drug interactions between rifampin and some ARVs that may compromise antiretroviral therapy (ART). Three studies presented at CROI provide clinicians with additional guidance on how to manage certain...
-
Bictegravir Approved for Initial ART, in Combination with TAF/FTC
Bictegravir (BIC), a new integrase inhibitor, was recently approved by the FDA for use in a single-pill coformulation with TAF/FTC (brand name: Biktarvy) as initial therapy and as a switch regimen for patients who are already on a suppressive ART regimen and who have no history of...
-
Undetectable = Untransmittable: Effective HIV Treatment Prevents HIV Transmission
In September 2017, the U.S. Centers for Disease Control and Prevention (CDC) officially recognized that suppressing HIV through antiretroviral therapy (ART) prevents sexual transmission of HIV. In a "Dear Colleague" letter, CDC officials said, "people who take ART daily as...
-
Doravirine in Initial Therapy: DRIVE-AHEAD Study
Doravirine (DOR) is an investigational NNRTI that currently is being developed in a coformulation with TDF and FTC. A Phase 3 comparison of DOR + 2 NRTIs (87% of study subjects were given TDF/FTC) and DRV/r + 2 NRTIs in initial therapy was presented at CROI earlier this year (DRIVE-FORWARD); the...
-
Bictegravir in Initial Therapy
Bictegravir (BIC) is an investigational integrase inhibitor that is being studied as part of a coformulation with tenofovir alafenamide (TAF) and emtricitabine (FTC). Two Phase 3 trials comparing a single-tablet regimen of BIC/TAF/FTC (50/25/200 mg) with regimens containing dolutegravir (DTG)...
-
On the Way: The First Protease Inhibitor-Based Single-Tablet Regimen
The EMERALD Study is a Phase 3 randomized (2:1), open-label, noninferiority study examining the strategy of switching patients with suppressed HIV RNA on a regimen consisting of a boosted protease inhibitor plus tenofovir disoproxil fumarate (TDF)/emtricitabine to an investigational single-...
-
CROI 2017: Failure of Dolutegravir Monotherapy
Leading up to this year, some researchers and clinicians had optimistically viewed dolutegravir an invincible ARV, a drug so mighty that it was unlikely to fail, and even more unlikely to be victim to emergent resistance mutations. Two presentations at CROI demonstrated the...
-
HIV Meds Update - RAPID: Immediate ART Initiation
This publication presents the results of San Francisco General Hospital's Ward 86 pilot study of immediate ART initiation. This RAPID program systematically offered ART to patients upon diagnosis of HIV; patients were referred from HIV testing sites in San Francisco. Of the 39 patients who...
-
HIV Meds Update: Treatment as Prevention: Suppressive ART, Condomless Sex, and HIV Transmission Risk - also a Word on HPTN 052
The PARTNER Study, a multisite European study, evaluated rates of HIV transmissions within serodifferent heterosexual and MSM couples (n = 548 and n = 340, respectively, contributed eligible data). The HIV-positive partners were on ART with HIV RNA levels of <200 copies/mL, and the couples...
-
HIV Meds Update: ART in Acute HIV--Decreasing HIV DNA
We know that very early treatment in acute HIV infection decreases HIV RNA; this study shows it also greatly decreases proviral DNA (and reservoir size). Researchers investigated 2 small cohorts of patients in Thailand with acute (and very early) HIV infection, 1 untreated and 1 treated with ART...
-
Efavirenz, Dolutegravir, and Darunavir: Pharmacokinetics during Pregnancy
Three studies presented at the 2016 Conference on Retroviruses and Opportunistic Infections (CROI) explored the pharmacokinetics of antiretrovirals administered during pregnancy. These studies support the use of standard-dose efavirenz, once-daily dolutegravir, and BID ritonavir-boosted...
-
Switching from TDF/FTC to TAF/FTC
Researchers at the 2016 Conference on Retroviruses and Opportunistic Infections presented results from a randomized double-blind, double-dummy switch study of TAF/FTC. Over 660 patients with virologic suppression on TDF/FTC-containing 3-drug regimens were either switched to TAF/FTC (200/10 mg...
-
Tissue Levels of TAF: Too Low for PrEP?
There was a pharmacokinetic study presented at the Conference on Retroviruses and Opportunistic Infections in Boston in February. It evaluated concentrations of tenofovir (TFV) and TFV-diphosphate (DP) in genital and rectal tissue. Also in anogenital fluid samples after administration of oral...
-
START-ing TEMPRANO: Early Initiation of Antiretroviral Therapy for HIV
The prevailing opinion among experts regarding the optimal CD4 T-cell count at which to start patients on antiretroviral therapy (ART) has shifted several times during the evolution of HIV treatment. These shifts reflect attempts to strike a balance between preventing HIV-associated illness and...
-
Cobicistat and Stribild Use in Patients with Renal Insufficiency
Co-Author: Susa Coffey, MD; Medical Editor, AETC National Resource Center
An open-label study is evaluating the renal safety of elvitegravir/cobicistat/emtricitabine/tenofovir (Stribild, or the "quad" pill) and cobicistat. For those patients with mild-to-...
-
Nov 3HIV and Injectable DrugsEvent type: Webinars
-
Aug 23 (All day)
-
Sep 25 (All day)
-
May 18HIV Vaccine Awareness DayEvent type: Awareness Days
-
Mar 6
-
Feb 7National Black HIV/AIDS Awareness DayEvent type: Awareness Days